Audited 2026-08-03 · Source read first-hand

Peptide telehealth programs: what they advertise against what is legal

We read the peptide telehealth comparison that currently ranks for this question and checked every compound in it against federal law. Of the 11 compounds we grade that those programs advertise, 5 can lawfully complete a prescription today. 5 cannot, because the substance itself is not eligible, and no prescriber, pharmacy or subscription changes that. The programs are real, their prescribers are licensed and their pharmacies are state-licensed. The gap is not in the clinic. It is in the compound.

What the source claims, and what we checked

The page in question is a four-program comparison, published July 2, 2026 and updated July 28, 2026. It carries an explicit affiliate disclosure, which we quote rather than paraphrase: “HealingMaps has affiliate relationships with the programs featured below and may earn a commission when readers sign up.” Two of the four programs are labelled Editorial Partner on the page itself. That is disclosed, and disclosure is the right thing to do. It is also the reason to check the claims rather than repeat them.

Its central claim is that the most-searched peptides, naming BPC-157, GHK-Cu injections and PT-141, previously “couldn’t be prescribed through legitimate national telehealth at all. That changed”. We fetched that page ourselves on 2026-08-03 and it returned HTTP 200 live, not from an archive, because an advertised price is a claim about today and an archived copy cannot establish one. Here is every compound it lists that we grade, with the legal answer taken from our own anchor rather than from the marketing copy.

Legal status is read from our legal-status record at build time, not typed into this page. Advertised menus were read from Healing Maps, The 4 Best Peptide Telehealth Programs of 2026, published July 2, 2026, updated July 28, 2026.

The GHK-Cu switch, which is the one to learn

GHK-Cu sits in a category of its own here, and the way it is sold is the most useful thing on this page. It is a legal cosmetic ingredient. You can buy it in a serum today with no prescription and no legal question at all, which is exactly why it appears on peptide menus. But the source page advertises GHK-Cu injections, and an injectable is not a cosmetic. It is a compounded drug, and it faces the same substance-eligibility condition as every other research peptide. The legality of the cream is doing the work of implying the legality of the vial. Once you have seen that move you will see it everywhere in this category.

What each program advertises

Prices and formats below are quoted as published, with the source's own hedging kept intact. We link none of these programs and have no affiliate relationship with any of them. They are named here as the subject of an audit, the same way the FDA warning letters name the sellers they were sent to.

The carve-out that gives it away

The same page tells readers who want TB-500 or KPV that “those remain clinic-only today”, and sends them to physical clinics instead. That concession is the tell. Those compounds went through the very same July 2026 advisory vote as the ones the page does advertise online, and they sit at the identical position under the statute: recommended by a committee, not yet acted on by the FDA, not eligible as a bulk substance. If the online route were genuinely open for the ones being sold, it would be open for these too. The line is drawn by what is being marketed, not by what the law says.

When a big name is reported to be entering peptides

In August 2026 the trade press reported that Hims & Hers Health, Inc. had signalled a move into peptides on its second-quarter earnings call. That coverage is secondary, all of it traces to the same call, and none of it is a product you can buy. So we checked the only record that settles the question, which is what the company has actually filed with the SEC. We did not listen to the call and we are not characterising what was said on it.

The company files as Hims & Hers Health, Inc. under CIK 0001773751 (NYSE: HIMS). Here is every search we ran against EDGAR full-text, with the result and the link, so you can re-run any of them yourself:

• Does any Hims filing from the week of the Q2 2026 earnings call match the plural term the trade coverage used?0 documents. Run this query (checked 2026-08-19)
• Across every Hims filing EDGAR indexes, how many match the plural term?3 documents, the newest filed 2026-02-23. Two are subsidiary lists attached to an annual report and one is a 2025 shareholder letter. Run this query (checked 2026-08-19)
• And the singular? EDGAR matches an exact phrase, so the singular and the plural are two different searches.14 documents. Exactly one of them falls in the week of the earnings call: the quarterly report filed 2026-08-10. Run this query (checked 2026-08-19)

One filing in that week matches: Form 10-Q, accession 0001773751-26-000163, for the quarter ended 2026-06-30, filed 2026-08-10. The document body was not read. www.sec.gov/Archives returns HTTP 403 to an automated fetcher, so we can say this filing matches the word and not what it says about it.

The more useful finding is the one about form type. No Hims 8-K filed in 2026 matches either the singular or the plural term. The 8-K filings that do match are older: 2025-11-03, 2025-05-05, 2025-02-24. An 8-K is the form a public company files to report a material event, which is what launching a product line into a new drug category would be. The absence is evidence about what has been formally announced. It is not evidence that nothing was said, and it is not evidence that nothing is planned.

None of this changes what is legal. 1 document: 2026-16296, published 2026-08-11, Substances Generally Recognized as Safe. That is a food-additive notice and it is not a compounding rule, so the answer is no. A company entering this category would face the same statute as everyone else on this page, so the questions below are the ones to ask whoever eventually sells you something, brand name or not.

What we do not have either

The honest half of this audit. We grade 10 compounds that could lawfully be supplied today, and our own access layer records a route for only 2 of them. That is a real gap on our side, and we would rather state it than let this page read as though the directory has the coverage problem solved. The difference is that a missing route here sends a reader nowhere, while an advertised route for an ineligible compound sends a reader somewhere that can stop supplying them without notice. If you want the route that does work today, it is set out in how to get peptides prescribed legally.

Four questions to ask any peptide telehealth program

1. Which bulk drug substance list is this compound on? There is a real answer for sermorelin and the approved drugs, and no answer for the rest. A program that cannot name the basis is telling you something.
2. Is the product you are selling me the topical or the injection? For GHK-Cu these are different legal categories and the marketing routinely merges them.
3. What happens to my protocol if the FDA declines the substance? The binding decision has not been made, so this is a live risk on every recommended compound, not a hypothetical.
4. Will you put the pharmacy name in writing? A state-licensed pharmacy is verifiable with a state board, and the ones with nothing to hide answer this in one line.

If what brought you here is weight loss rather than recovery peptides, the compounded GLP-1 market is a different lane with its own economics, and we cover it at GLP-1 Picks.